Servier's Clinical and Real-World Data at 2025 SNO Congress Showcase Leadership in IDH-Mutant Glioma
Safety data from a Phase 1b study evaluating the combination of VORANIGO and standard of care chemotherapy in high grade IDH-mutant gliomas will be featured in a rapid-fire oral presentation BOSTON, ...
Late-breaking data from the pivotal Phase 3 INDIGO study strengthen clinical evidence of vorasidenib in IDH-mutant diffuse glioma First data of vorasidenib in combination with pembrolizumab to profile ...
Servier serves up phase 3 brain tumor win at interim analysis, validating $1.8B buyout of Agios unit
Servier’s $1.8 billion oncology bet has delivered a phase 3 win. Vorasidenib, a candidate covered by the French drugmaker’s buyout of Agios Pharmaceuticals' cancer unit, beat placebo on the primary ...
Servier's Clinical and Real-World Data at 2025 SNO Congress Showcase Leadership in IDH-Mutant Glioma
Presentations include seven company-sponsored abstracts and two investigator-initiated studies Oral presentation to highlight new analysis comparing volumetric and bidirectional assessments in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback